Selected Announcements
1. Ping An of China: Net profit returned to the mother in 2022 was 83.774 billion yuan, a year-on-year decrease of 17.56%
$PING AN (02318.HK)$The results for the year ended December 31, 2022 were announced. In 2022, the company achieved operating profit attributable to shareholders of the parent company of 148.365 billion yuan, an increase of 0.3% over the previous year; operating ROE of 17.9%; and net profit attributable to shareholders of the parent company of 83.774 billion yuan, a decrease of 17.56% over the previous year. A full-year dividend was distributed to shareholders in cash of RMB 2.42 per share, an increase of 1.7% over the previous year.
2. Zhongtong Express: adjusted net profit for FY2022 was 6.806 billion yuan, up 37.6% year on year
$ZTO EXPRESS-SW (02057.HK)$It was announced that in the fourth quarter of 2022, revenue was RMB 9.871.3 billion, up 7.1% year on year; gross profit was 2,772.6 billion yuan, up 23.2% year on year; net profit was $2129.3 billion, up 21.8% year on year; and adjusted net profit was $2.120 billion, up 21.5% year on year. In fiscal year 2022, revenue was 35.377 billion yuan, up 16.3% year on year; gross profit was 9.0393 billion yuan, up 37.2% year on year; net profit was 6.659 billion yuan, up 41.6% year on year; and adjusted net profit was RMB 6.806 billion, up 37.6% year on year.
3. Datang New Energy: The power generation in February 2023 was about 2.49 million megawatt-hours, an increase of 16.57% over the previous year
$DATANG RENEW (01798.HK)$An announcement was issued. In February 2023, the Company and its subsidiaries completed a power generation capacity of 2,485,843 megawatt-hours according to the consolidated statement, an increase of 16.57% over 2022. The total power generation capacity completed in the first 2 months was 5.655 million megawatt-hours, an increase of 35.37% over the previous year.
4. Kangfang Biotech - B: Product market sales in 2022 were 1.104 billion yuan, up 422% year on year
$AKESO-B (09926.HK)$An announcement was issued. For the year ended December 31, 2022, product market sales were RMB 1,104 billion, up 422% year on year; gross profit for 2022 was RMB 743.5 million, up 283% year on year, mainly due to a sharp increase in revenue.
5. Hong Kong Stock Exchange: Apply for additional RMB counters for HKEx stock trading
$HKEX (00388.HK)$Announcing the announcement, Hong Kong Stock Exchange Limited, a wholly-owned subsidiary of the company, published a notice on December 13, 2022 on the launch of the HKD-RMB dual counter model to further support the development of RMB in the Hong Kong stock market. The addition of RMB counter transactions under the dual counter model will further promote the process of RMB internationalization, support and strengthen Hong Kong's role as a global offshore RMB business hub and international financial center. The dual counter arrangement will provide investors with new trading currency options and possibly more liquidity opportunities. The proposed dual-counter bookmaker mechanism will also allow market bookmakers to provide liquidity and minimize the price difference between the Hong Kong dollar counter and the RMB counter. HKEx announced that it has submitted an application for the establishment of an additional RMB counter for stock trading.
IPO
Dashi Shares (01405), starting March 16, will offer a stock offering price of HK$46-55 per share
Financial data
Ping An of China (02318): In 2022, the parent operating profit was 148.365 billion yuan, and the dividend per share increased 1.7% year on year
Zhongtong Express-SW (02057): The adjusted net profit for FY2022 was 6.806 billion yuan, up 37.6% year on year
Cornerstone Pharmaceutical-B (02616) announced annual results: revenue increased 97.51% to 481 million yuan, losses narrowed sharply
Kangfang Bio-B (09926): 2022 product market sales of 1.104 billion yuan increased 422% year-on-year
CGN Electric Power (01816)'s net profit in 2022 was about 9,965 billion yuan, up 2.06% year on year
GDS - SW (09698) 2022 net revenue reached 9.325.6 billion yuan, adjusted EBITDA increased 14.8% to 4.251 billion yuan
Kingdee International (00268) announced annual results, revenue growth of about 16.6% to 4.866 billion yuan, loss of about 389 million yuan
Cheung Kong Infrastructure Group (01038) increased its annual net profit by 3.1% to HK$7.748 billion, final interest of HK$1.83
Net profit attributable to owners of China Merchants Land (00978) fell by about 41.2% to HK$330 million with final interest of HK$0.03 million
Profit attributable to shareholders of Electric Energy Industrial (00006) for the year reached HK$5.65 billion, final interest of $2, 4 cents
Yuexiu Real Estate (00123): Core net profit of $4.24 billion for the full year of 2022, final interest of HK$0.307
Shanshui Cement (00691)'s profit in 2022 was about 749 million yuan, a year-on-year decrease of 73.0%
Yuyuan Group (00551)'s annual net profit increased by 157.5% to US$296 million with final interest of HK$0.70
Nexteer (01316) 2022 net profit fell 51.02% to $58.013 million with final interest of $0.0047
China Aviation Science and Industry (02357) annual revenue of 63.639 billion yuan increased 5.54% year-on-year
Operational data
Air China (00753)'s passenger turnover in February rose 71.2% year on year, up 6.7% month on month
China Southern Airlines Co., Ltd. (01055): Passenger capacity investment in February increased 27.51% year on year
China Eastern Airlines Co., Ltd. (00670) saw a 43.47% year-on-year increase in passenger turnover in February
China Taibao (02601): China Pacific Life's original premium income of 69.763 billion yuan in the first two months fell 5.6% year on year
Datang New Energy (01798) completed power generation capacity of 2,486,000 megawatt-hours in February, an increase of 16.57% over the same period last year
Mergers and acquisitions
China Jinmao (00817) plans to acquire 37.7464% of Nanjing International's shares for 2,060 million yuan
Guolian Securities (01456): The controlling shareholder won 30.3% of Minsheng Securities's shares for 9.105 billion yuan
Important matters
Hong Kong Stock Exchange (00388): Application for additional RMB counter for HKEx stock trading
Gaosi Medical (02407): Signed a cooperation with GEUDER to localize medical devices for vitrectomy surgery
Innovation Qizhi (02121) and Lanzhou Technology signed a strategic cooperation agreement
Corning Jerry Pharmaceuticals-B (09966): A phase IA/IB clinical study conducted by JSKN003 in China to treat advanced HER2-expressing solid tumors completed first patient administration
Heyu-B (02256): Pimicotinib (ABSK021) was approved by the US FDA to enter a randomized, double-blind, placebo-controlled, multicenter phase III clinical study on the efficacy and safety of patients with giant tenosynoid tumors
Fu Hong Han Lin (02696): The clinical trial application for HLX51 for the treatment of advanced/metastatic solid tumors and lymphoma was approved by the China Drug Administration
Nuohui Health-B (06606): Starting March 20, the company's Chinese and English stock abbreviations will no longer be marked “B”
China Aviation Science and Industry (02357) signed a mutual supply agreement for products and services of Hafei Group
Haobai International (08431) and Dongan Xiqi sign a strategic cooperation agreement
Repurchase cancellation
AIA (01299) spent HK$132 million to repurchase 1,6352 million shares on March 15
Zhonglian Heavy Industries (01157) spent 27.97 million yuan to repurchase about 4.33 million A-shares on March 15
Standard Chartered Group (02888) spent £19816 million to repurchase 2,912,900 shares on March 14
Taikoo Corporation B (00087) spent HK$5.34 million to repurchase 557,500 shares on March 15
Equity incentives
Ali Health (00241) grants 360,000 restricted share units
Editor/Somer